Benzinga | Jan 11, 2022 07:10AM EST

CareDx Partners With Multiple Biotechnology Companies To Use AlloCell In CAR T-Cell Therapy Clinical Studies

CareDx, Inc. (NASDAQ:CDNA) -- The Transplant Company(tm) focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced recent drug development collaborations with three leading cell therapy biopharmaceutical companies to use CareDx's AlloCell(tm) surveillance in the respective companies' ongoing CAR T-cell therapy clinical studies.



CareDx AlloCell is a highly sensitive, next-generation sequencing surveillance solution for patients who have received engineered or non-engineered allogeneic cell therapies for cancer or other autoimmune conditions. AlloCell is being used in several biopharmaceutical company clinical studies for investigational allogeneic CAR T-cell therapies in clinical development. AlloCell assesses the cellular kinetics of allogeneic cellular therapies, such as the expansion and persistence of allogeneic cells, which may correlate with patients' response to treatment or adverse events.

"As an innovator in transplant for over two decades, we are excited to have signed recent partnerships of AlloCell with three leading developers of allogeneic CAR T-cell therapies," said Reg Seeto, CEO and President of CareDx. "AlloCell will be used by our biopharma partners to advance their programs in this new and exciting field of cell therapies."

Allogeneic cell therapies represent a rapidly growing area of clinical research, with investigational therapeutics being evaluated in oncology, cardiovascular, neurological, autoimmune, and infectious diseases. The AlloCell addressable market in hematological and solid tumor cancer patients is estimated to be over $5.5 billion.1